
The VictoryShares US EQ Income Enhanced Volatility Wtd ETF aims to mirror the investment outcomes of the Nasdaq Victory US Large Cap High Dividend 100 Long/Cash Volatility Weighted Index (referred to as the "Long/Cash Index"), prior to the deduction of fees and expenses. This fund utilizes a distinctive "Volatility Weighting" approach, which integrates fundamental criteria with volatility-based weighting in an effort to achieve superior performance compared to conventional market-capitalization-weighted index strategies. A key characteristic of the Long/Cash Index is its adaptive mechanism…
Is CDC's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim an

VictoryShares US EQ Income Enhanced Volatility Wtd ETF (NASDAQ: CDC - Get Free Report) announced a monthly dividend on Wednesday, October 7th. Stockholders of record on Thursday, October 8th will be given a dividend of $0.2024 per share on Friday, October 9th. This represents a $2.43 dividend on an annualized basis and a dividend yield of

Shares of VictoryShares US EQ Income Enhanced Volatility Wtd ETF (NASDAQ: CDC - Get Free Report) passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $75.91 and traded as low as $71.43. VictoryShares US EQ Income Enhanced Volatility Wtd ETF shares last traded at $71.56,

MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #GDIT--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent and fair for all, has been selected by General Dynamics Information Technology (GDIT) to support the World Trade Center (WTC) Health Program. The WTC Health Program is a limited federal health care program established under the James Zadroga 9/11 Health and Compensation Act of 2010 (Extended in 2015). It provides nationwid.

U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually Kamada's Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.